Tamaulipas Residents Grapple with Questions over ‘Abdala’ Vaccine
In the Mexican state of Tamaulipas, uncertainty lingers as residents question the effectiveness and safety of the domestically produced ‘Abdala’ COVID-19 vaccine. The concerns come amidst a global vaccine supply crunch and a rapidly evolving pandemic.
Developed by Cuba‘s Finlay Institute, the Abdala vaccine has proven to be nearly 92% effective in clinical trials, according to its developers. However, the World Health Organization (WHO) has not yet approved the vaccine, fueling hesitancy among some Tamaulipas residents.
"People are confused, they don’t know what to believe," said Maria, a nurse in the state capital, Ciudad Victoria, who preferred not to share her last name. She and her colleagues have received Abdala doses but are puzzled about its legitimacy without WHO endorsement. Maria added, "Who should we trust when everyone seems to have their own version of the truth?"
The lack of global recognition for the Abdala vaccine stems partly from Cuba’s limited pharmaceutical industry, which has yet to supply significant quantities to international markets for rigorous, independent testing.
Dr. Fernando Martinez, a public health specialist in Tamaulipas, acknowledged the uncertainty but emphasized, "We’re dealing with a pandemic situation, and we need to use all available tools. The Abdala vaccine, despite not having WHO approval, is a tool that can help us control the spread of the virus."
With the delta variant surging globally and the vaccination rollout facing setbacks in many countries, Tamaulipas residents find themselves in a complex and unprecedented situation. The decision to trust and accept the Abdala vaccine remains a delicate balance between hope, skepticism, and the urgent need to protect public health.
